Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
Diabetic neuropathy is a severe complication of diabetes mellitus (DM) that considerably worsens the patients quality of life and reduces life expectancy.The FIELD study for the first time demonstrated the ability of fenofibrate to prevent macro- and microvacular complications in patientswith DM2 re...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2010-03-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6014 |
| _version_ | 1797255297806368768 |
|---|---|
| author | Olga Nikolaevna Tkacheva Irina Mikhailovna Novikova Natalya Viktorovna Sharashkina Khyadi Magometovna Torshkhoeva Nadezhda Konstantinovna Runikhina |
| author_facet | Olga Nikolaevna Tkacheva Irina Mikhailovna Novikova Natalya Viktorovna Sharashkina Khyadi Magometovna Torshkhoeva Nadezhda Konstantinovna Runikhina |
| author_sort | Olga Nikolaevna Tkacheva |
| collection | DOAJ |
| description | Diabetic neuropathy is a severe complication of diabetes mellitus (DM) that considerably worsens the patients quality of life and reduces life expectancy.The FIELD study for the first time demonstrated the ability of fenofibrate to prevent macro- and microvacular complications in patientswith DM2 regardless of glycated hemoglobin level and dyslipidemia at the early stage of the disease. Neuropathy being a manifestation of microangiopathy,it suggests the possibility to treat this disorder with fenofibrate.Aim. To study effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy. Materials and methods. The present study included 73 patients with DM2 randomized into 2 groups to receive standard therapy (antihypertensiveand glucose control, statins) or fenofibrate (Tricor 145 mg, Solvay Pharma) in addition to the standard treatment. Results. Positive effect of fenofibrate on autonomous and peripheral neuropathy was apparent within 6 months after the onset of therapy when thesought parameters of AP, glycemia, and lipid spectrum were achieved. Fenofibrate improved cardiovascular function, reduced cardiac rhythm variability;QT length and dispersion, pain and paresthesia thereby enhancing quality of life and preventing cardiovascular catastrophes including death. Conclusion. It is concluded that supplementation of standard therapy of DM with fenofibrate is both safe and pathogenetically sound. |
| first_indexed | 2024-03-08T15:22:37Z |
| format | Article |
| id | doaj.art-aa80eabb72264d718010560156b4bb37 |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2024-04-24T22:03:37Z |
| publishDate | 2010-03-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-aa80eabb72264d718010560156b4bb372024-03-20T11:47:55ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782010-03-01131333910.14341/2072-0351-60145972Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathyOlga Nikolaevna Tkacheva0Irina Mikhailovna Novikova1Natalya Viktorovna Sharashkina2Khyadi Magometovna Torshkhoeva3Nadezhda Konstantinovna Runikhina4V.I. Kulakov Research Centre of Obstetrics, Gynecology and Perinatology, MoscowV.I. Kulakov Research Centre of Obstetrics, Gynecology and Perinatology, MoscowV.I. Kulakov Research Centre of Obstetrics, Gynecology and Perinatology, MoscowV.I. Kulakov Research Centre of Obstetrics, Gynecology and Perinatology, MoscowRussian State Medical University, MoscowDiabetic neuropathy is a severe complication of diabetes mellitus (DM) that considerably worsens the patients quality of life and reduces life expectancy.The FIELD study for the first time demonstrated the ability of fenofibrate to prevent macro- and microvacular complications in patientswith DM2 regardless of glycated hemoglobin level and dyslipidemia at the early stage of the disease. Neuropathy being a manifestation of microangiopathy,it suggests the possibility to treat this disorder with fenofibrate.Aim. To study effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy. Materials and methods. The present study included 73 patients with DM2 randomized into 2 groups to receive standard therapy (antihypertensiveand glucose control, statins) or fenofibrate (Tricor 145 mg, Solvay Pharma) in addition to the standard treatment. Results. Positive effect of fenofibrate on autonomous and peripheral neuropathy was apparent within 6 months after the onset of therapy when thesought parameters of AP, glycemia, and lipid spectrum were achieved. Fenofibrate improved cardiovascular function, reduced cardiac rhythm variability;QT length and dispersion, pain and paresthesia thereby enhancing quality of life and preventing cardiovascular catastrophes including death. Conclusion. It is concluded that supplementation of standard therapy of DM with fenofibrate is both safe and pathogenetically sound.https://www.dia-endojournals.ru/jour/article/view/6014diabetic neuropathydislipidemiafenofibrate |
| spellingShingle | Olga Nikolaevna Tkacheva Irina Mikhailovna Novikova Natalya Viktorovna Sharashkina Khyadi Magometovna Torshkhoeva Nadezhda Konstantinovna Runikhina Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy Сахарный диабет diabetic neuropathy dislipidemia fenofibrate |
| title | Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy |
| title_full | Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy |
| title_fullStr | Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy |
| title_full_unstemmed | Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy |
| title_short | Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy |
| title_sort | effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy |
| topic | diabetic neuropathy dislipidemia fenofibrate |
| url | https://www.dia-endojournals.ru/jour/article/view/6014 |
| work_keys_str_mv | AT olganikolaevnatkacheva effectsoffenofibrateinpatientswithtype2diabetesmellituscomplicatedbydiabeticneuropathy AT irinamikhailovnanovikova effectsoffenofibrateinpatientswithtype2diabetesmellituscomplicatedbydiabeticneuropathy AT natalyaviktorovnasharashkina effectsoffenofibrateinpatientswithtype2diabetesmellituscomplicatedbydiabeticneuropathy AT khyadimagometovnatorshkhoeva effectsoffenofibrateinpatientswithtype2diabetesmellituscomplicatedbydiabeticneuropathy AT nadezhdakonstantinovnarunikhina effectsoffenofibrateinpatientswithtype2diabetesmellituscomplicatedbydiabeticneuropathy |